6461.TWO Intech Biopharm Ltd
- Market cap
- TWD 1.82B
- P/E
- -
- P/B
- 2.11x
- ROE
- -48.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6461.TWO undervalued?
Graham numberThe Graham number of Intech Biopharm Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Intech Biopharm Ltd fundamental analysis
No fundamental analysis for Intech Biopharm Ltd yet.
Intech Biopharm Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Intech Biopharm Ltd
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, S…
Full company profileIntech Biopharm Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Intech Biopharm Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 16.6M | 17.2M | 16.7M | 21.1M | 38.9M | 23.6M | 25.8M | 39.8M | 108M | 72.9M |
| Gross Profit | 9.55M | 8.92M | -146M | -139M | -119M | -147M | -164M | -158M | -111M | -179M |
| Operating Income | -247M | -231M | -300M | -234M | -282M | -305M | -304M | -356M | -365M | -409M |
| EBITDA | -221M | -200M | -218M | -149M | -197M | -219M | -220M | -247M | -257M | -303M |
| Net Income | -239M | -222M | -311M | -250M | -302M | -328M | -338M | -368M | -389M | -429M |
| EPS | -3.37 | -2.74 | -3.01 | -2.42 | -2.89 | -2.82 | -2.81 | -2.63 | -2.18 | -3.89 |
| Balance Sheet | ||||||||||
| Total Assets | 2.24B | 2.51B | 2.61B | 2.62B | 2.60B | 2.55B | 2.71B | 2.40B | 2.35B | 2.30B |
| Total Liabilities | 887M | 1.02B | 1.04B | 1.29B | 1.26B | 1.52B | 1.54B | 1.58B | 1.25B | 1.40B |
| Shareholders' Equity | 1.36B | 1.49B | 1.57B | 1.33B | 1.34B | 1.03B | 1.17B | 814M | 1.10B | 894M |
| Cash & Short-term Investments | 108M | 128M | 172M | 305M | 335M | 375M | 598M | 199M | 16.8M | 95.4M |
| Total Debt | - | - | - | 1.18B | 1.15B | 1.41B | 1.44B | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -145M | -232M | -189M | -167M | -201M | -190M | -204M | -269M | -361M | -339M |
| Capital Expenditure | 258M | 204M | 51.3M | 48.2M | 21.3M | 11.0M | 30.2M | 43.6M | 64.0M | 47.3M |
| Free Cash Flow | -408M | -437M | -240M | -216M | -222M | -201M | -234M | -313M | -425M | -387M |
| Ratios | ||||||||||
| ROE | -17.7% | -14.9% | -19.8% | -18.8% | -22.6% | -31.8% | -28.9% | -45.2% | -35.3% | -48.0% |
| ROA | -10.7% | -8.8% | -12.0% | -9.6% | -11.6% | -12.9% | -12.5% | -15.4% | -16.5% | -18.7% |
| Net Profit Margin | -1,441.0% | -1,288.6% | -1,866.6% | -1,186.3% | -775.7% | -1,386.5% | -1,307.6% | -925.6% | -361.8% | -588.7% |
| Debt to Equity | - | - | - | 0.89x | 0.86x | 1.37x | 1.23x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Intech Biopharm Ltd dividends
Intech Biopharm Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 618.578:1000 on Sep 2, 2026.
Who owns Intech Biopharm Ltd
- Insiders 49.43%
- Institutions 4.70%
- Public & others 45.87%
- Shares outstanding 68.2M
- Free float 58.5M
Intech Biopharm Ltd company profile
- Company name
- Intech Biopharm Ltd
- Ticker
- 6461.TWO
- ISIN
- TW0006461007
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 96
- Fiscal year end
- December
- Address
- No. 36, Ruiguang Road, Taipei, Taiwan, 114
- Phone
- 886 2 7721 8877
- Website
- intechbiopharm.com
About Intech Biopharm Ltd
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was founded in 2010 and is headquartered in Taipei, Taiwan.
Intech Biopharm Ltd management
5- Mr. Wei Xiu WuGeneral Manager
- Mr. Qirui LiRepresentative
- Mr. Xianzhi PiSpecial Assistant to the Chairman and Strategic Development Coordinator
- Dr. Manish ChawlaPresident & Chief Scientific Officer
- Ms. Chien-Yiu YangFinance Division Head